PubMed ID:
22797645
Public Release Type:
Journal
Publication Year: 2012
Affiliation: UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA. mfried@med.unc.edu
DOI:
https://doi.org/10.1001/jama.2012.8265
Authors:
Walton A,
Seeff L,
Bodenheimer HC,
Laurin J,
McFann KK,
Shader RI,
Blumenthal M,
Belle SH,
Wahed AS,
Hawke RL,
Reddy KR,
Meyers CM,
Doo E,
Doo E,
Meyers C,
Duffy L,
Zadorozny E,
Wahed A,
Lawlor S,
Kurs-Lasky M,
Bowen J,
Belle S,
Wirjosemito A,
Reddy K,
Hoofnagle J,
Davis P,
Dougherty KA,
Borg E,
Elliott S,
Evon D,
Fried MW,
Batey B,
Verma M,
Navarro V,
Miller C,
Gupta D,
Colagreco J,
Afdhal N,
Navarro VJ,
Fried MW,
Kennedy C,
Kaplan DE,
Soule T,
Schrieber S,
Howell M,
Hawke R,
Silymarin in NASH and C Hepatitis (SyNCH) Study Group,
Afdhal N
Studies:
Silymarin Trial for Hepatitis C and NASH
The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy.